Novel Weight Loss Pill Orforglipron Outperforms Oral Semaglutide in Blood Sugar Control and Weight Loss

Lancet study finds orforglipron pill leads to 8% weight loss and better sugar control than semaglutide. Explore the Phase 3 results for this new diabetes drug.

By: AXL Media

Published: Feb 26, 2026, 6:35 AM EST

Source: The information in this article was sourced from The Lancet

A New Frontier in Oral Diabetes Management

The landscape of type 2 diabetes treatment is shifting toward more flexible, high-efficacy oral options. Results from the ACHIEVE-3 Phase 3 trial, published in The Lancet, have identified orforglipron as a potent new contender in the GLP-1 receptor agonist (RA) market. In a direct comparison with oral semaglutide—currently the only available oral GLP-1 RA—orforglipron demonstrated a superior ability to lower blood sugar levels and facilitate weight reduction over a 52-week period. This clinical breakthrough suggests that the next generation of metabolic medications may provide stronger results while removing the restrictive fasting requirements that currently burden patients.

Comparative Efficacy in Blood Sugar Regulation

The ACHIEVE-3 trial involved more than 1,500 participants across 131 medical research centers globally, including sites in the USA, China, and Japan. Participants were randomized to receive either orforglipron (12 mg or 36 mg) or oral semaglutide (7 mg or 14 mg). The data revealed that participants on both doses of orforglipron achieved a greater mean reduction in blood sugar levels than those on either semaglutide dose. This enhanced glycemic control is a critical metric for preventing long-term diabetic complications, positioning orforglipron as a potentially more effective tool for managing the complexities of type 2 diabetes.

Accelerated Weight Loss for Metabolic Syndrome

Beyond glycemic control, the study measured the impact of these medications on body mass. Starting from an average baseline weight of 97 kg, participants taking orforglipron lost between 6% and 8% of their total body weight after one year. In contrast, those taking oral semaglutide recorded a more modest loss of 4% to 5%. This significant gap in weight loss performance highlights orforglipron’s potential as a dual-action therapy that addresses both the caloric and hormonal imbalances associated with metabolic syndrome and type 2 diabetes.